Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to Medicare and Medicaid policy. Monitor the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169). Monitor and engage on legislative and administrative action related to Medicare inpatient reimbursement for cell and gene therapies. H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025. H.R. 7871, Medicaid VBPs for Patients Act (MVP Act). S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BAYER CORPORATION (CONSOLIDATED REPORT) via BAYER CORPORATION (CONSOLIDATED REPORT)
2026 · third_quarter · Q3
Monitor and engage on legislative and administrative action on appropriations and budget. Monitor and engage on legislative and administrative action related to the uniformity of pesticide labeling. Monitor and engage on legislative and administrative action related to FY2027 Interior, Environment, and Related Agencies Appropriations Acts. Monitor and engage on legislative and administrative action related to FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Acts. H.R. 9171, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2027. H.R. 9260, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027.
Source: Senate LDA
Monitor and engage on legislative and administrative action related to Medicare and Medicaid policy. Monitor the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169). Monitor and engage on legislative and administrative action related to Medicare inpatient reimbursement for cell and gene therapies. H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025. S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025.
Safe Step Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney disease patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 5509, Safe Step Act. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. H.R. 8933, Dietary Supplements Access Act. H.R. 9090, Advancing Menopause Care and Mid-Life Womens Health Act. S. 2903, Safe Step Act. S. 3122, Better Food Disclosure Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act. S. 4503, Advancing Menopause Care and Mid-Life Womens Health Act. S. 4587, Dietary Supplements Access Act. S. 5260, Stroke Act.
Support and Defend Our Military Personnel and Their Families Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney disease patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 5509, Safe Step Act. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. H.R. 8933, Dietary Supplements Access Act. H.R. 9090, Advancing Menopause Care and Mid-Life Womens Health Act. S. 2903, Safe Step Act. S. 3122, Better Food Disclosure Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act. S. 4503, Advancing Menopause Care and Mid-Life Womens Health Act. S. 4587, Dietary Supplements Access Act. S. 5260, Stroke Act.
Support and Defend Our Military Personnel and Their Families Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act.
Dietary Supplement Regulatory Uniformity Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney disease patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 5509, Safe Step Act. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. H.R. 8933, Dietary Supplements Access Act. H.R. 9090, Advancing Menopause Care and Mid-Life Womens Health Act. S. 2903, Safe Step Act. S. 3122, Better Food Disclosure Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act. S. 4503, Advancing Menopause Care and Mid-Life Womens Health Act. S. 4587, Dietary Supplements Access Act. S. 5260, Stroke Act.
Dietary Supplement Regulatory Uniformity Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act.
MVP Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to Medicare and Medicaid policy. Monitor the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169). Monitor and engage on legislative and administrative action related to Medicare inpatient reimbursement for cell and gene therapies. H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025. H.R. 7871, Medicaid VBPs for Patients Act (MVP Act). S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025.
Dietary Supplements Access Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney disease patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 5509, Safe Step Act. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. H.R. 8933, Dietary Supplements Access Act. H.R. 9090, Advancing Menopause Care and Mid-Life Womens Health Act. S. 2903, Safe Step Act. S. 3122, Better Food Disclosure Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act. S. 4503, Advancing Menopause Care and Mid-Life Womens Health Act. S. 4587, Dietary Supplements Access Act. S. 5260, Stroke Act.
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney disease patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 5509, Safe Step Act. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. H.R. 8933, Dietary Supplements Access Act. H.R. 9090, Advancing Menopause Care and Mid-Life Womens Health Act. S. 2903, Safe Step Act. S. 3122, Better Food Disclosure Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act. S. 4503, Advancing Menopause Care and Mid-Life Womens Health Act. S. 4587, Dietary Supplements Access Act. S. 5260, Stroke Act.
Department of the Interior, Environment, and Related Agencies Appropriations Act, 2027
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action on appropriations and budget. Monitor and engage on legislative and administrative action related to the uniformity of pesticide labeling. Monitor and engage on legislative and administrative action related to FY2027 Interior, Environment, and Related Agencies Appropriations Acts. Monitor and engage on legislative and administrative action related to FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Acts. H.R. 9171, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2027. H.R. 9260, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027.
Department of the Interior, Environment, and Related Agencies Appropriations Act, 2027
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action on appropriations and budget. Monitor and engage on legislative and administrative action related to the uniformity of pesticide labeling. Monitor and engage on legislative and administrative action related to FY2027 Interior, Environment, and Related Agencies Appropriations Acts. Monitor and engage on legislative and administrative action related to FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Acts. H.R. 9171, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2027. H.R. 9260, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action on appropriations and budget. Monitor and engage on legislative and administrative action related to the uniformity of pesticide labeling. Monitor and engage on legislative and administrative action related to FY2027 Interior, Environment, and Related Agencies Appropriations Acts. Monitor and engage on legislative and administrative action related to FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Acts. H.R. 9171, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2027. H.R. 9260, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action on appropriations and budget. Monitor and engage on legislative and administrative action related to the uniformity of pesticide labeling. Monitor and engage on legislative and administrative action related to FY2027 Interior, Environment, and Related Agencies Appropriations Acts. Monitor and engage on legislative and administrative action related to FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Acts. H.R. 9171, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2027. H.R. 9260, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027.
Safe Step Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney disease patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 5509, Safe Step Act. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. H.R. 8933, Dietary Supplements Access Act. H.R. 9090, Advancing Menopause Care and Mid-Life Womens Health Act. S. 2903, Safe Step Act. S. 3122, Better Food Disclosure Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act. S. 4503, Advancing Menopause Care and Mid-Life Womens Health Act. S. 4587, Dietary Supplements Access Act. S. 5260, Stroke Act.
Better FDA Act of 2025
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney disease patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 5509, Safe Step Act. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. H.R. 8933, Dietary Supplements Access Act. H.R. 9090, Advancing Menopause Care and Mid-Life Womens Health Act. S. 2903, Safe Step Act. S. 3122, Better Food Disclosure Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act. S. 4503, Advancing Menopause Care and Mid-Life Womens Health Act. S. 4587, Dietary Supplements Access Act. S. 5260, Stroke Act.
Dietary Supplement Listing Act of 2026
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney disease patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 5509, Safe Step Act. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. H.R. 8933, Dietary Supplements Access Act. H.R. 9090, Advancing Menopause Care and Mid-Life Womens Health Act. S. 2903, Safe Step Act. S. 3122, Better Food Disclosure Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act. S. 4503, Advancing Menopause Care and Mid-Life Womens Health Act. S. 4587, Dietary Supplements Access Act. S. 5260, Stroke Act.
Dietary Supplement Listing Act of 2026
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act.
CLEAR LABELS Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney disease patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 5509, Safe Step Act. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. H.R. 8933, Dietary Supplements Access Act. H.R. 9090, Advancing Menopause Care and Mid-Life Womens Health Act. S. 2903, Safe Step Act. S. 3122, Better Food Disclosure Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act. S. 4503, Advancing Menopause Care and Mid-Life Womens Health Act. S. 4587, Dietary Supplements Access Act. S. 5260, Stroke Act.
CLEAR LABELS Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act.
Advancing Menopause Care and Mid-Life Women’s Health Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney disease patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 5509, Safe Step Act. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. H.R. 8933, Dietary Supplements Access Act. H.R. 9090, Advancing Menopause Care and Mid-Life Womens Health Act. S. 2903, Safe Step Act. S. 3122, Better Food Disclosure Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act. S. 4503, Advancing Menopause Care and Mid-Life Womens Health Act. S. 4587, Dietary Supplements Access Act. S. 5260, Stroke Act.
Dietary Supplements Access Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney disease patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 5509, Safe Step Act. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. H.R. 8933, Dietary Supplements Access Act. H.R. 9090, Advancing Menopause Care and Mid-Life Womens Health Act. S. 2903, Safe Step Act. S. 3122, Better Food Disclosure Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act. S. 4503, Advancing Menopause Care and Mid-Life Womens Health Act. S. 4587, Dietary Supplements Access Act. S. 5260, Stroke Act.
Stroke Act
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney disease patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 5509, Safe Step Act. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. H.R. 8933, Dietary Supplements Access Act. H.R. 9090, Advancing Menopause Care and Mid-Life Womens Health Act. S. 2903, Safe Step Act. S. 3122, Better Food Disclosure Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act. S. 4503, Advancing Menopause Care and Mid-Life Womens Health Act. S. 4587, Dietary Supplements Access Act. S. 5260, Stroke Act.
EPIC Act of 2025
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to Medicare and Medicaid policy. Monitor the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169). Monitor and engage on legislative and administrative action related to Medicare inpatient reimbursement for cell and gene therapies. H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025. H.R. 7871, Medicaid VBPs for Patients Act (MVP Act). S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025.
EPIC Act of 2025
Client: BAYER CORPORATION (CONSOLIDATED REPORT) · Firm: BAYER CORPORATION (CONSOLIDATED REPORT)
Monitor and engage on legislative and administrative action related to Medicare and Medicaid policy. Monitor the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169). Monitor and engage on legislative and administrative action related to Medicare inpatient reimbursement for cell and gene therapies. H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025. S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025.
Monitor and engage on legislative and administrative action related to Medicare and Medicaid policy. Monitor the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169). Monitor and engage on legislative and administrative action related to Medicare inpatient reimbursement for cell and gene therapies. H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025. H.R. 7871, Medicaid VBPs for Patients Act (MVP Act). S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025.
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney disease patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 5509, Safe Step Act. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. H.R. 8933, Dietary Supplements Access Act. H.R. 9090, Advancing Menopause Care and Mid-Life Womens Health Act. S. 2903, Safe Step Act. S. 3122, Better Food Disclosure Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act. S. 4503, Advancing Menopause Care and Mid-Life Womens Health Act. S. 4587, Dietary Supplements Access Act. S. 5260, Stroke Act.
Monitor and engage on legislative and federal activity related to tax reform. Monitor and engage on legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. Monitor and engage on legislative and administrative action related to including dietary supplements as reimbursable expenses in tax-preferred savings accounts. Monitor and engage on legislative and administrative issues related to foreign tax credit regulations. Monitor and engage on the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169), including the section 45Z tax credit and the sustainable aviation fuel tax credit. Monitor and engage on the implementation of One Big Beautiful Bill Act (Pub. Law. 119-21).
Filing targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Natl Economic Council (NEC), Natl Security Council (NSC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Fish & Wildlife Service (USFWS), U.S. Geological Survey (USGS), U.S. Trade Representative (USTR), White House Office
BAYER CORPORATION (CONSOLIDATED REPORT) via BAYER CORPORATION (CONSOLIDATED REPORT)
2026 · second_quarter · Q2
Monitor and engage on legislative and administrative action on appropriations and budget. Monitor and engage on legislative and administrative action related to the uniformity of pesticide labeling. Monitor and engage on legislative and administrative action related to FY2027 Interior, Environment, and Related Agencies Appropriations Acts. Monitor and engage on legislative and administrative action related to FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Acts. H.R. 9171, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2027. H.R. 9260, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027.
Monitor and engage on legislative and administrative action related to Medicare and Medicaid policy. Monitor the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169). Monitor and engage on legislative and administrative action related to Medicare inpatient reimbursement for cell and gene therapies. H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025. S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025.
Monitor and engage on legislative and federal activity related to tax reform. Monitor and engage on legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. Monitor and engage on legislative and administrative action related to including dietary supplements as reimbursable expenses in tax-preferred savings accounts. Monitor and engage on legislative and administrative issues related to foreign tax credit regulations. Monitor and engage on the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169), including the section 45Z tax credit and the sustainable aviation fuel tax credit. Monitor and engage on the implementation of One Big Beautiful Bill Act (Pub. Law. 119-21).
Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to regulation of over-the-counter medicines. Monitor and engage on legislative and administrative action related to dietary supplements, including FDA regulation of ingredients. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to access to treatments for kidney patients. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. Monitor and engage on legislative and administrative action related to FDA regulation of cell and gene therapies. Monitor and engage on legislative and administrative action related to Parkinsons disease. Monitor and engage on legislative and administrative action related to federal investment in biotech development and manufacturing. H.R. 6118, Support and Defend Our Military Personnel and Their Families Act. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. S. 3677, Dietary Supplement Listing Act of 2026. S. 3788, CLEAR Labels Act.
Filing targets: Agriculture, Dept of (USDA), Bureau of Land Management (BLM), Commerce, Dept of (DOC), Council on Environmental Quality (CEQ), Defense, Dept of (DOD), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Interior, Dept of (DOI), Natl Economic Council (NEC), Natl Security Council (NSC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Agency for International Development (USAID), U.S. Geological Survey (USGS), U.S. Trade Representative (USTR), White House Office